Skip to content
MedsAcross

Medicine

Fenofibric acid 135 mg delayed-release capsule

Available on requestPrescription onlyUS FDAGeneric name

Fenofibric acid 135 mg delayed-release capsule is a generic prescription medicine for oral use, made by 4 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20º to 25ºC (68º to 77ºF), excursions permitted to 15° to 30°C (59°…

Key facts

Active ingredient (INN)
Fenofibric acid
Brand
Sold under the generic name
Strength
135 mg
Dosage form
Delayed-release capsule
Route
Oral
Packs
30 capsules, 90 capsules, 1000 capsules and 6 more
Manufacturers
Alembic PharmaceuticalsIndiaAurobindo PharmaIndiaAmneal Pharmaceuticals of New YorkLeading Pharma
Origin register
US FDA, United States
Storage
Store at 20º to 25ºC (68º to 77ºF), excursions permitted to 15° to 30°C (59° to 86°F). Protect from moisture.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
15 May 2017
Identifiers
RxCUI 828373, 828379DailyMed set ID daa488be-f580-430c-a72c-80ac31bb3e40, c880d43a-fa8c-4f7a-a488-419bae7cc311, 9ad201de-fa62-4c49-bc61-ee09b9ba434c +2NDC 69315-282, 46708-245, 59651-217 +2Application ANDA211626, ANDA208705, ANDA212598 +1

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
30 capsule, delayed release in 1 bottle46708-245-30Alembic PharmaceuticalsIndia18 May 2017
90 capsule, delayed release in 1 bottle46708-245-90Alembic PharmaceuticalsIndia18 May 2017
1000 capsule, delayed release in 1 bottle46708-245-91Alembic PharmaceuticalsIndia18 May 2017
30 capsule, delayed release in 1 bottle62332-245-30Alembic PharmaceuticalsIndia15 May 2017
90 capsule, delayed release in 1 bottle62332-245-90Alembic PharmaceuticalsIndia15 May 2017
1000 capsule, delayed release in 1 bottle62332-245-91Alembic PharmaceuticalsIndia15 May 2017
90 capsule, delayed release in 1 bottle59651-217-90Aurobindo PharmaIndia25 July 2019
90 capsule, delayed release in 1 bottle0115-1325-10Amneal Pharmaceuticals of New York1 June 2024
90 capsule, delayed release in 1 bottle69315-282-09Leading Pharma18 July 2019

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 14 August 2009Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Fenofibric acid

Clinical summary

Fenofibric acid is a peroxisome proliferator receptor alpha agonist indicated as adjunctive therapy to diet, among other approved uses. It is available as delayed-release capsules for oral use. MedsAcross supplies Fenofibric acid for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Fenofibric acid

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Fenofibric acid 135 mg delayed-release capsule for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.